A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Clinical trial NCT06459180 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06459180
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-24
- Primary completion
- 2028-06-15
- Enrollment
- 686
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.